Sophia Genetics

SOPHiA GENETICS is an American Swiss biotechnology company with its headquarters in Lausanne and Boston. It provides genomic and radiomic analysis for hospitals. The company was ranked among the 50 smartest companies by the MIT Technology Review in 2017. 
History.
Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011 as start-up at École Polytechnique Fédérale de Lausanne (EPFL). 
In September 2017, the company introduced an analytical software platform, which helps to interpret circulating tumor DNA and circulating tumour cells in blood, urine, cerebral spinal fluid and other liquid samples.
In 2018, the company set up its first research and development centre in France and made acquisition of a France-based molecular biology and genetic analytics software development company, Interactive Biosoftware.
In 2020, the company appointed Troy Cox, former board of directors member, as its new chairman, and Lara Hashimoto as chief business officer.
Funding.
In September 2013, as part of a Series A round of funding, Sophia Genetics received $3 million for its medical software platform. The funding round was led by a London-based venture capital firm Balderton Capital with participation from Invoke Capital, and Belgian pharmaceutical entrepreneur Marc Coucke.
In 2014, as part of a Series B round of funding, the company raised $13.75 million from Swisscom and Endeavour Vision.
In December 2015, as part of a Series C round of funding, Sophia Genetics raised $15 million from Omega Pharma founder and healthcare scion Marc Coucke.
In September 2017, as part of a Series D round of funding, the company received $30 million from UK-based VC firm Balderton Capital, 360 Capital Partners, and existing investors including Invoke Capital and Alychlo.
In January 2019, as part of a Series E round of funding, the company raised $77 million. The round was led by Generation Investment Management and included early backers Idinvest Partners, Balderton Capital, and Alychlo.
In October 2020, as part of a Series F round of funding, the company raised $110 million. The round was led by aMoon a health-tech & life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group. 
Partnership.
Sophia Genetics formed partnerships with Integrated DNA Technologies and Paragon Genomics, next-generation sequencing (NGS) assay development company, to provide COVID-19 test kits 
The company also partners with Illumina and MGI, a subsidiary of BGI Group, to enable their users to access SOPHiA Platform for data analysis and interpretation.